Regulation of Mdm2 compartmentalization
Mdm2 区室化的调控
基本信息
- 批准号:7064306
- 负责人:
- 金额:$ 23.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-05-11 至 2006-12-31
- 项目状态:已结题
- 来源:
- 关键词:DNA damageapoptosisbiological signal transductionepidermal growth factorinsulinlike growth factorkinase inhibitormitogen activated protein kinasemitogensneoplasm /cancer geneticsneoplastic growthnuclear proteinsnuclear transportoncoproteinsp53 gene /proteinphosphorylationposttranslational modificationsprotein localizationsite directed mutagenesissmall interfering RNAtissue /cell culture
项目摘要
DESCRIPTION (provided by applicant): Mitogens play an integral role in resistance, proliferation, and survival of human tumors. Unraveling the intricate signal transduction pathways that regulate tumorigenesis is a critical step in identifying new therapeutic targets for disruption to impede the progression of cancer. It is not clear as to what extent tumor derived mitogens such as IGF-1 and EGF-1 signal to activate the oncogenic activity of the murine double minute protein (Mdm2). Mdm2 plays a role in tumorigenesis in part through the disruption of the tumor suppressor protein p53. It has been assumed that Mdm2 nuclear localization was a passive process requiring only the nuclear localization sequence (NLS). We show that IGF-1 activated PI3-K/Akt signaling induces the phosphorylation and nuclear translocation of Mdm2, which disrupts p53 activity and facilitates p53 degradation. The p53-Mdm2 complex is exported from the nucleus for both proteins to be degraded. Thus, it seems likely that there is a second signal transduction pathway responsible for mediating Mdm2 nuclear export. We hypothesize that Mdm2 nuclear export is regulated by post-translational modifications mediated by the mitogen activated protein kinase pathway, and culminates in the inactivation of p53. The specific aims in this proposal are designed to ascertain how signal transduction pathways directly regulate Mdm2 and its activity to block p53 function. [Aim 1] To elucidate the signal transduction pathway that mediates nuclear export of Mdm2 by post-translational modifications. We will use selective pharmacological inhibitors to signaling kinases, and dominant negative kinases to block nuclear export of Mdm2. We will determine post-translational modifications to Mdm2 by mass spectrometry in response to growth factor simulation and pharmacological blockade of growth factor stimulated signaling pathways. The identification of phosphorylation sites required for export will be alter to a non-phosphorylatable amino acids to confirm the requirement of these sites to promote Mdm2 nuclear export. [Aim 2] This specific aim is to characterize the effect of Mdm2 nuclear export on p53 activity and stability in response to growth factors and DNA damage. Preventing Mdm2 nuclear export should have a dramatic effect on p53 activity. We will examine p53 transcriptional activity when Mdm2 is unable to exit the nucleus. We will also determine if p53 ubiquitation mediated by Mdm2 occurs in the nucleus or cytoplasm and in what compartment the p53-Mdm2 complex is degraded. Biologically, we will test if Mdm2 rendered in the nucleus can attenuate p53 dependent apoptosis in response to DNA damage. Considering that nuclear Mdm2 is prevalent in human cancer, upon completion of this proposal we will understand the contribution of signal transduction pathways in promoting Mdm2 nuclear export and potentially how to regulate export of nuclear Mdm2 to increase p53 dependent apoptosis.
描述(申请人提供):有丝分裂原在人类肿瘤的耐药、增殖和存活中起着不可或缺的作用。解开调控肿瘤发生的复杂信号转导通路是确定新的治疗靶点的关键一步,通过干扰来阻止癌症的进展。目前尚不清楚肿瘤来源的丝裂原如IGF-1和EGF-1信号在多大程度上激活了小鼠双微小蛋白(MDM2)的致癌活性。MDM2在肿瘤发生中的作用部分是通过破坏肿瘤抑制蛋白P53来实现的。人们认为MDM2的核定位是一个被动的过程,只需要核定位序列(NLS)。我们发现IGF-1激活的PI3-K/Akt信号诱导MDM2的磷酸化和核转位,从而破坏P53的活性,促进P53的降解。P53-MDM2复合体从细胞核中排出,使两种蛋白质都被降解。因此,似乎有可能存在第二条信号转导途径,负责调节MDM2核输出。我们假设MDM2核输出是由丝裂原活化蛋白激酶途径介导的翻译后修饰调控的,最终导致P53失活。这项建议的具体目的是确定信号转导通路如何直接调节MDM2及其阻断P53功能的活性。[目的1]阐明翻译后修饰介导MDM2核输出的信号转导途径。我们将使用选择性的药物抑制剂来信号转导激酶,并使用显性负性激酶来阻断MDM2的核输出。我们将通过质谱学确定MDM2的翻译后修饰,以响应生长因子模拟和药物阻断生长因子刺激的信号通路。确定出口所需的磷酸化位点将改为非磷酸化氨基酸,以确认这些位点促进MDM2核出口的要求。[目的2]研究MDM2核出口对P53活性和稳定性的影响,以应对生长因子和DNA损伤。阻止MDM2核出口应该会对P53活性产生巨大影响。当MDM2无法退出细胞核时,我们将检测P53的转录活性。我们还将确定MDM2介导的P53泛化是否发生在细胞核或细胞质中,以及P53-MDM2复合体在哪个隔室降解。从生物学上讲,我们将测试在细胞核中呈现的MDM2是否可以减弱DNA损伤引起的p53依赖的细胞凋亡。考虑到核MDM2在人类癌症中的普遍存在,在完成这一提议后,我们将了解信号转导通路在促进MDM2核输出中的贡献,以及潜在地如何调节核MDM2的输出以增加P53依赖的细胞凋亡。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LINDSEY D MAYO其他文献
LINDSEY D MAYO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LINDSEY D MAYO', 18)}}的其他基金
Regulation of Mdm2 activity by kinase signaling pathways
激酶信号通路对 Mdm2 活性的调节
- 批准号:
8835069 - 财政年份:2013
- 资助金额:
$ 23.61万 - 项目类别:
Regulation of Mdm2 activity by kinase signaling pathways
激酶信号通路对 Mdm2 活性的调节
- 批准号:
9242979 - 财政年份:2013
- 资助金额:
$ 23.61万 - 项目类别:
Regulation of Mdm2 activity by kinase signaling pathways
激酶信号通路对 Mdm2 活性的调节
- 批准号:
8700353 - 财政年份:2013
- 资助金额:
$ 23.61万 - 项目类别:
Regulation of Mdm2 activity by kinase signaling pathways
激酶信号通路对 Mdm2 活性的调节
- 批准号:
8575588 - 财政年份:2013
- 资助金额:
$ 23.61万 - 项目类别:
Regulation of Mdm2 activity by kinase signaling pathways
激酶信号通路对 Mdm2 活性的调节
- 批准号:
9050651 - 财政年份:2013
- 资助金额:
$ 23.61万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
- 批准号:31970691
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
- 批准号:31900527
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
姜黄素与TRAIL的协同抗肿瘤机制研究
- 批准号:31101223
- 批准年份:2011
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
- 批准号:81100502
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Role of Frizzled 5 in NK cell development and antiviral host immunity
Frizzled 5 在 NK 细胞发育和抗病毒宿主免疫中的作用
- 批准号:
10748776 - 财政年份:2024
- 资助金额:
$ 23.61万 - 项目类别:
Causes and Downstream Effects of 14-3-3 Phosphorylation in Synucleinopathies
突触核蛋白病中 14-3-3 磷酸化的原因和下游影响
- 批准号:
10606132 - 财政年份:2024
- 资助金额:
$ 23.61万 - 项目类别:
A HUMAN IPSC-BASED ORGANOID PLATFORM FOR STUDYING MATERNAL HYPERGLYCEMIA-INDUCED CONGENITAL HEART DEFECTS
基于人体 IPSC 的类器官平台,用于研究母亲高血糖引起的先天性心脏缺陷
- 批准号:
10752276 - 财政年份:2024
- 资助金额:
$ 23.61万 - 项目类别:
The role of BET proteins in pathological cardiac remodeling
BET蛋白在病理性心脏重塑中的作用
- 批准号:
10538142 - 财政年份:2023
- 资助金额:
$ 23.61万 - 项目类别:
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 23.61万 - 项目类别:
The Gut as a Target to Improve Outcomes in Sepsis
肠道作为改善脓毒症预后的目标
- 批准号:
10552403 - 财政年份:2023
- 资助金额:
$ 23.61万 - 项目类别:
The role of osteoblast progenitors in response to bone anabolic agents
成骨细胞祖细胞对骨合成代谢剂的反应的作用
- 批准号:
10404415 - 财政年份:2023
- 资助金额:
$ 23.61万 - 项目类别:
Mechanisms of Parp inhibitor-induced bone marrow toxicities
Parp 抑制剂诱导骨髓毒性的机制
- 批准号:
10637962 - 财政年份:2023
- 资助金额:
$ 23.61万 - 项目类别:
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
- 批准号:
10637251 - 财政年份:2023
- 资助金额:
$ 23.61万 - 项目类别:
REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary Hypertension
REVAMP-PH:重新利用缬沙坦可以预防肺动脉高压
- 批准号:
10642368 - 财政年份:2023
- 资助金额:
$ 23.61万 - 项目类别: